Effect of sotatercept on multicomponent improvement in the PULSAR study
M. Hoeper (Hannover, Germany), H. Ghofrani (Giessen, Germany), J. Gibbs (London, United Kingdom), M. Gomberg-Maitland (Washington DC, United States), M. Humbert (Le Kremlin-Bicêtre, France), V. Mclaughlin (Ann Arbor, MI, United States), I. Preston (Boston, MA, United States), R. Souza (São Paulo, Brazil), A. Waxman (Boston, MA, United States), J. Pena (Rahway, NJ, United States), S. Manimaran (Rahway, NJ, United States), M. Fowler (Rahway, NJ, United States), D. Badesch (Aurora, CO, United States)
Source: International Congress 2022 – Novelties in pulmonary hypertension management
Session: Novelties in pulmonary hypertension management
Session type: Oral Presentation
Number: 2273
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Hoeper (Hannover, Germany), H. Ghofrani (Giessen, Germany), J. Gibbs (London, United Kingdom), M. Gomberg-Maitland (Washington DC, United States), M. Humbert (Le Kremlin-Bicêtre, France), V. Mclaughlin (Ann Arbor, MI, United States), I. Preston (Boston, MA, United States), R. Souza (São Paulo, Brazil), A. Waxman (Boston, MA, United States), J. Pena (Rahway, NJ, United States), S. Manimaran (Rahway, NJ, United States), M. Fowler (Rahway, NJ, United States), D. Badesch (Aurora, CO, United States). Effect of sotatercept on multicomponent improvement in the PULSAR study. 2273
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|